MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q2
hinzugefügt 11.08.2022
Affimed N.V. Anteile 2011-2026 | AFMD
Anteile Jährlich Affimed N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 120 M | 64.2 M | 64.2 M | 60.5 M | 43.8 M | 33.2 M | 33.3 M | 24 M | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 120 M | 24 M | 55.3 M |
Anteile Vierteljährlich Affimed N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 120 M | - | - | - | 79.2 M | - | - | - | 62.4 M | - | - | - | 62.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 120 M | 62.4 M | 80.9 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
9.88 M | $ 8.67 | 0.35 % | $ 85.7 M |  USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.6 | -1.64 % | $ 8.66 B |  Australia |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
85.3 M | $ 3.27 | 4.98 % | $ 279 M | USA |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
9.27 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioNTech SE
BNTX
|
244 M | $ 99.34 | 2.73 % | $ 27.2 B | Germany |
 |
bluebird bio
BLUE
|
110 M | - | - | $ 546 M | USA |
 |
Burford Capital Limited
BUR
|
219 M | $ 4.72 | 5.23 % | $ 751 M |  Britain |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Cabaletta Bio
CABA
|
100 M | $ 3.23 | 0.94 % | $ 325 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 21.6 | 1.12 % | $ 1.01 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
39.7 M | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
61.8 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
257 M | $ 1.54 | 4.76 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 3.05 | 4.45 % | $ 5.02 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
107 M | $ 4.21 | 0.36 % | $ 450 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 25.33 | 5.01 % | $ 3.22 B | USA |
 |
Chimerix
CMRX
|
88.6 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
34.4 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
66.4 M | $ 33.59 | 3.07 % | $ 2.23 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.49 | 1.1 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
6.35 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
443 K | $ 2.46 | -1.99 % | $ 1.09 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
115 M | - | - | $ 1.2 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |